U.S. Stock Market Movement | Biotechnology company Attovia Therapeutics (ATTO.US) has debuted on Nasdaq, closing up 28.82% on its first day of trading.

On Wednesday, the biotechnology company Attovia Therapeutics (ATTO.US) officially debuted on NASDAQ, with its stock rising 28.82% on its first day, closing at $21.9. The IPO price was $17. Founded in 2022, Attovia's core technology, the "ATTOBODY" platform, is a biotechnology platform based on biparatopic nanobodies, exclusively licensed from Alamar Biosciences (ALMR.US). This platform enables the development of multispecific antibody therapies targeting complex immune checkpoints.